I took a very quick look. 100% GM-CSF + trastuzumab vs. 89.4% GM-CSF only. Looking at earlier trials it seems quite extraordinary. What threw me for a loop was adding GM-CSF. Apparently GM-CSF aids trastuzumab which is a bit puzzling because overexpression of GM-CSF is considered a negative indicator for cancer. GM-CSF is also something that leronlimab downregulates. In general you wouldn't want to see a complete elimination of GM-CSF so I wonder if trastuzumab almost completely downregulates it.